APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Somatostatin Analogues (LA SSAs)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Long-acting Somatostatin Analogues (LA SSAs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025188 pages

Choose your research edition.

Industry ResearchLong-acting Somatostatin Analogues (LA SSAs) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Somatostatin Analogues (LA SSAs) Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Long-acting Somatostatin Analogues (LA SSAs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Long-acting Somatostatin Analogues (LA SSAs) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting Somatostatin Analogues (LA SSAs) include Chiesi Farmaceutici S.p.A, Ipsen, Recordati Rare Diseases, Novartis and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Somatostatin Analogues (LA SSAs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Somatostatin Analogues (LA SSAs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Somatostatin Analogues (LA SSAs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Somatostatin Analogues (LA SSAs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Somatostatin Analogues (LA SSAs) Segment by Company

Chiesi Farmaceutici S.p.A

Ipsen

Recordati Rare Diseases

Novartis

Teva

Long-acting Somatostatin Analogues (LA SSAs) Segment by Type

Injections

Oral Capsules

Long-acting Somatostatin Analogues (LA SSAs) Segment by Application

Neuroendocrine Tumors

Acromegaly

Other

Long-acting Somatostatin Analogues (LA SSAs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Somatostatin Analogues (LA SSAs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Somatostatin Analogues (LA SSAs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Somatostatin Analogues (LA SSAs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Somatostatin Analogues (LA SSAs) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting Somatostatin Analogues (LA SSAs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Long-acting Somatostatin Analogues (LA SSAs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Long-acting Somatostatin Analogues (LA SSAs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Long-acting Somatostatin Analogues (LA SSAs) Industry Trends Table 2. Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers Table 3. Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges Table 4. Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints Table 5. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Manufacturers Table 9. Global Long-acting Somatostatin Analogues (LA SSAs) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Long-acting Somatostatin Analogues (LA SSAs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Long-acting Somatostatin Analogues (LA SSAs) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Product Type & Application Table 13. Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Somatostatin Analogues (LA SSAs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Injections Table 17. Major Manufacturers of Oral Capsules Table 18. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 20. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (K Units) Table 21. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2021-2026) Table 22. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2027-2032) Table 23. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2026) & (K Units) Table 25. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2027-2032) & (K Units) Table 26. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2021-2026) Table 27. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Neuroendocrine Tumors Table 29. Major Manufacturers of Acromegaly Table 30. Major Manufacturers of Other Table 31. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 33. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (K Units) Table 34. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2021-2026) Table 35. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2027-2032) Table 36. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2026) & (K Units) Table 38. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2027-2032) & (K Units) Table 39. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2021-2026) Table 40. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2027-2032) Table 41. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2026) & (K Units) Table 43. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region (2021-2026) Table 44. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 48. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 49. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 51. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 58. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region (2021-2026) Table 62. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region (2027-2032) Table 63. Chiesi Farmaceutici S.p.A Company Information Table 64. Chiesi Farmaceutici S.p.A Business Overview Table 65. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 67. Chiesi Farmaceutici S.p.A Recent Development Table 68. Ipsen Company Information Table 69. Ipsen Business Overview Table 70. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 72. Ipsen Recent Development Table 73. Recordati Rare Diseases Company Information Table 74. Recordati Rare Diseases Business Overview Table 75. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 77. Recordati Rare Diseases Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 82. Novartis Recent Development Table 83. Teva Company Information Table 84. Teva Business Overview Table 85. Teva Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 87. Teva Recent Development Table 88. Key Raw Materials Table 89. Raw Materials Key Suppliers Table 90. Long-acting Somatostatin Analogues (LA SSAs) Distributors List Table 91. Long-acting Somatostatin Analogues (LA SSAs) Customers List Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Long-acting Somatostatin Analogues (LA SSAs) Product Image Figure 2. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting Somatostatin Analogues (LA SSAs) Sales (2021-2032) & (K Units) Figure 5. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Long-acting Somatostatin Analogues (LA SSAs) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Injections Image Figure 9. Oral Capsules Image Figure 10. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2021-2032) Figure 13. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2021-2032) Figure 16. Neuroendocrine Tumors Image Figure 17. Acromegaly Image Figure 18. Other Image Figure 19. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2021-2032) Figure 22. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2021-2032) Figure 25. North America Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2032) Figure 27. U.S. Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2032) Figure 32. Germany Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2032) Figure 39. China Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2032) Figure 47. Brazil Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Long-acting Somatostatin Analogues (LA SSAs) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Figure 58. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Figure 60. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Long-acting Somatostatin Analogues (LA SSAs) Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Long-acting Somatostatin Analogues (LA SSAs) Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Injections
  • Oral Capsules
Applications
  • Neuroendocrine Tumors
  • Acromegaly
  • Other
Companies covered
  • Chiesi Farmaceutici S.p.A
  • Ipsen
  • Recordati Rare Diseases
  • Novartis
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Long-acting Somatostatin Analogues (LA SSAs) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Long-acting Somatostatin Analogues (LA SSAs) Market Dynamics
  1. 2.1 Long-acting Somatostatin Analogues (LA SSAs) Industry Trends
  2. 2.2 Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers
  3. 2.3 Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges
  4. 2.4 Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints
3 Long-acting Somatostatin Analogues (LA SSAs) Market by Manufacturers
  1. 3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Long-acting Somatostatin Analogues (LA SSAs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting Somatostatin Analogues (LA SSAs) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Product Type & Application
  7. 3.7 Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting Somatostatin Analogues (LA SSAs) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting Somatostatin Analogues (LA SSAs) Tier 1, Tier 2, and Tier 3
4 Long-acting Somatostatin Analogues (LA SSAs) Market by Type
  1. 4.1 Long-acting Somatostatin Analogues (LA SSAs) Type Introduction
  2. 4.1.1 Injections
  3. 4.1.2 Oral Capsules
  4. 4.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type
  5. 4.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032)
  7. 4.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type
  9. 4.3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2032)
  11. 4.3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2021-2032)
5 Long-acting Somatostatin Analogues (LA SSAs) Market by Application
  1. 5.1 Long-acting Somatostatin Analogues (LA SSAs) Application Introduction
  2. 5.1.1 Neuroendocrine Tumors
  3. 5.1.2 Acromegaly
  4. 5.1.3 Other
  5. 5.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application
  6. 5.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032)
  8. 5.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2021-2032)
  9. 5.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application
  10. 5.3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2032)
  12. 5.3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2021-2032)
6 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region
  1. 6.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2026)
  4. 6.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region
  1. 7.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region
  2. 7.1.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2021-2026)
  4. 7.1.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2027-2032)
  5. 7.1.4 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032)
  8. 7.2.2 North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032)
  11. 7.3.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chiesi Farmaceutici S.p.A
  2. 8.1.1 Chiesi Farmaceutici S.p.A Company Information
  3. 8.1.2 Chiesi Farmaceutici S.p.A Business Overview
  4. 8.1.3 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  6. 8.1.5 Chiesi Farmaceutici S.p.A Recent Developments
  7. 8.2 Ipsen
  8. 8.2.1 Ipsen Company Information
  9. 8.2.2 Ipsen Business Overview
  10. 8.2.3 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  12. 8.2.5 Ipsen Recent Developments
  13. 8.3 Recordati Rare Diseases
  14. 8.3.1 Recordati Rare Diseases Company Information
  15. 8.3.2 Recordati Rare Diseases Business Overview
  16. 8.3.3 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  18. 8.3.5 Recordati Rare Diseases Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Teva
  26. 8.5.1 Teva Company Information
  27. 8.5.2 Teva Business Overview
  28. 8.5.3 Teva Long-acting Somatostatin Analogues (LA SSAs) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  30. 8.5.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Somatostatin Analogues (LA SSAs) Value Chain Analysis
  2. 9.1.1 Long-acting Somatostatin Analogues (LA SSAs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Somatostatin Analogues (LA SSAs) Production Mode & Process
  6. 9.2 Long-acting Somatostatin Analogues (LA SSAs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Somatostatin Analogues (LA SSAs) Distributors
  9. 9.2.3 Long-acting Somatostatin Analogues (LA SSAs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst